You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
心通醫療(02160.HK)向4C Medical追加不逾2,500萬美元投資
阿思達克 11-05 08:23
心通醫療(02160.HK)公佈,對4C Medical Technologies作出不超過2,500萬美元的追加投資。完成後,公司連同其全資附屬Derryhill Global將成爲4C Medical的最大股東,而4C Medical不會成爲公司的附屬。 作爲追加投資的重大誘因,4C Medical同意向公司授出其臨牀前階段三尖瓣產品(4C三尖瓣產品)於中國、香港、澳門及臺灣的獨家商業權利。4C Medical與公司將訂立三尖瓣產品商業協議,並採用與AltaValve協議基本相似的條款及商業安排開發及分銷4C三尖瓣產品。 公司指出,推動對4C Medical作出追加投資的主要原因爲其近期研發的有利結果,其在研產品帶來的業務協同作用及臨牀合作。公司認爲4C Medical的在研產品(包括4C三尖瓣產品)可進一步豐富公司在中國尚待開發的龐大市場的產品提供。 4C Medical在美國從事二尖瓣及三尖瓣器械的研發,其主要產品爲創新TMV置換醫療器械AltaValve。心通醫療已與4C Medical訂立AltaValve分銷及生產協議,以獲授權於內地、香港、澳門及臺灣分銷AltaValve的獨家商業權益,亦尋求通過本地製造的產品獲得國家藥監局成功註冊。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account